An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 2, 2004, Pages 187-195

  Golański, Jacek ^a   Nocuń, Marek ^a   Rózalski, Marcin ^a   Drygas, Wojciech ^a   Watała, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

'Aspirin resistance'; Acetylsalicylic acid; Blood platelet reactivity; PFA 100; Platelet response to aspirin

Indexed keywords

ACETYLSALICYLIC ACID; ASPIRIN PROTECT;

ANALYZER; ARTICLE; BIOLOGICAL MONITORING; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; METHODOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ASPIRIN; COLLAGEN; DRUG RESISTANCE; EPINEPHRINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; RISK; SENSITIVITY AND SPECIFICITY;

EID: 1642335090     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200403000-00011     Document Type: Article

References (38)

1. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993; 24:345-350.
2. Gum PA, Kottka-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
3. Weber A, Zimmerman KC, Meyer-Kichrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible faactor in aspirin resistance [Letter]. The Lancet 1999; 353:800.
4. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316-321.
5. Golanski J, Chizynski K, Golanski R, Watala C. Use of platelet function analyzer PFA-100 and whole blood aggregometry to monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it possible to reliably monitor antiplatelet treatment using routine laboratory diagnostic methods? Pol Arch Med Wewn 2000; 104:355-361.
6. Jilma B, Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 2001; 88:1348-1349.
7. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 2001; 14:57-62.
8. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995; 21(suppl 2):106-112.
9. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
10. Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002; 108:43-47.
11. Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol 1984; 37:874-878.
12. Falcon C, Arnout J, Vermylen J. Platelet aggregation in whole blood - studies with a platelet counting technique - methodological aspects and some applications. Thromb Haemost 1989; 61:423-428.
13. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13:37-40.
14. Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb-Hemost 1996; 2:241-249.
15. Kottke Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999; 5:122-130.
16. Watala C, Golanski J, Rozalski M, Bonder MA, Luzak B, Baraniak J, et al. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb Res 2003; 109:299-306.
17. Rozalski M, Boncler M, Golanski J, Watala C. Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation. Biochem Pharmacol 2001; 62: 1399-1408.
18. Watala C, Waczulikova I, Wieclawska B, Rozalski M, Gresner P, Gwozdzinski K, et al. Merocyanine 540 as a fluorescent probe of altered membrane phospholipid asymmetry in activated whole blood platelets. Cytometry 2002; 49:119-133.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
20. Altman DG, Bland JM. Measurment in medicine: the analysis of method comparision studies. Statistician 1983; 32:307-317.
21. Zar J. Biostatistical analysis. Upper Saddle River, NJ: Prentice-Hall International, Simon & Schuster/A Viacom Company; 1999.
22. Buchanan M-R, Schwartz L, Bourassa M, Brister S-J, Peniston C-M. Results of the BRAT study - a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16:1385-1390.
23. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965.
24. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88:711-715.
25. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250:63-66.
26. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108:542-547.
27. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002; 13:49-56.
28. Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326:82-83.
29. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1:1710-1713.
30. Schror K. Aspirin and platelets: the antipletelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23:349-356.
31. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41:966-968.
32. Matsuno H, Kozawa O, Nagashima S, Kanamaru M, Uematsu T. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates. Br J Pharmacol 1999; 127:1129-1134.
33. Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BM, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther 1999; 37:584-588.
34. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108:37-42.
35. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250:63-66.
36. Berkowitz SD, Frelinger AL, Hillman RS. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998; 136:351-365.
37. Favaloro EJ. Clinical application of the PFA-100(R). Curr Opin Hematol 2002; 9:407-415.
38. de Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003; 1:2048-2050.